Vision for precision
Treat what you see.
Track what you treat.
Beamrion is building the first real-time MRI-guided, beam-agnostic particle therapy platform — bringing non-invasive surgical precision to cancer treatment and beyond.
About
A Helmholtz spin-off solving the blind spot of particle therapy.
Particle therapy delivers its maximum dose exactly at the tumor and stops. But today's standard of care relies on X-ray or CT image guidance, offering poor soft-tissue contrast and no information on tumor motion.
If you cannot see and track the tumor, you cannot hit it precisely. The result: large safety margins, long treatment courses and many indications that stay untreated.
Beamrion closes that gap with in-beam magnetic resonance imaging — born from years of research at the Helmholtz association and OncoRay — National Center for Radiation Research in Oncology.
The Product
The world's first in-beam MRI scanner for real-time adaptive particle therapy.
- Unsurpassed soft-tissue image quality during irradiation
- Live tumor motion tracking at high temporal resolution
- Beam gating triggered directly by what the scanner sees
- AI-driven real-time adaptive workflows
- Beam delivery with non-invasive surgical precision
- Compact footprint designed for existing treatment rooms
Real-time beam adaptation
Live MR imaging during irradiation triggers beam gating for moving tumors — e.g. lung, liver, pancreas.
Beam-agnostic platform
Not a stand-alone therapy system. Fits horizontal beam lines and operates with all major particle therapy vendors.
Multi-position treatment
Compact open-sky magnet with a smaller footprint and multi-position in-magnet treatment.
New indications
Unlock treatment indications beyond oncology to cardiology and neurology.
Safer treatment
Tighter margins through real-time image guidance.
Shorter courses
Hypofractionation and adaptive workflows reduce overall treatment times.
Broader access
Immediately treat moving tumors and soft-tissue indications that are out of reach today.
Platform economics
One platform that integrates with existing particle therapy systems.
TECHNOLOGY
Proven development from proof of concept to product.
In-beam MRI — developed step by step.
BEAMRION takes particle therapy out of its niche and brings it to full potential.
Our in-beam MRI has moved from world's first experimental evidence to an integrated system design: imaging before an active scanning particle therapy beam line, engineered for excellent image quality and precise beam delivery at the same time.
Each development stage has been validated in a real particle therapy environment — a de-risked path from proof of concept towards a clinical product.
FOUNDER TEAM
Strong team expertise.
Clinic
Radiation oncology leadership with deep clinical trial and patient-pathway experience.
Physics
Years of research in MR imaging and particle therapy dose delivery.
Engineering
Magnet, hardware and software engineering for integrated clinical systems.
Regulatory
Medical device regulatory and quality expertise for certification-ready development.
Business
Start up set up, marketing, strategic partnerships, go-to-market planning and investor outreach.
Supported by an advisory board spanning MRI technology, medical device commercialization, clinical practice and patient representation.
CONTACT FOR INVESTORS, CLIENTS AND PARTNERS
A vision for precision. Join the next chapter of cancer care
Beamrion is a Helmholtz spin-off, developing a first-of-its-kind in-beam MRI system for real-time adaptive particle therapy.
If you want to learn more, request the investor deck or schedule a call with the team.
Our pre-sales and collaboration network is open. University hospitals, private clinics, radiation oncologists, particle therapy centres and technology partners are equally welcome — simply switch to the CLINIC & PARTNER ENQUIRY form.
First-mover technology
The first MRI scanner designed to operate in combination with an active scanning particle therapy beam line.
De-risked development path
Built on years of research and public funding with proven feasibility in clinical environments.
Broad indication potential
Moving beyond oncology to non-cancerous diseases in cardiology and neurology.
Newsletter
Stay close to the beam
Occasional updates on our technology, milestones and company news. Double opt-in — you will receive a confirmation email. Unsubscribe any time.